Arecor Therapeutics (FRA:6UI) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6UI Arecor Therapeutics PLC FRA:6UI
37 GF Score
Price €0.63
GF Value €0.45
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:6UI vs VRTX, REGN, RVMD: Short Interest Comparison

For the Biotechnology subindustry, Arecor Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's Short Interest falls into.


FRA:6UI
37GF Score
Arecor Therapeutics PLC FRA:6UI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.63 is trading 40% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:6UI:

  • Short Interest:
  • GF Value™: €0.45 vs. price of €0.63 (40% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for FRA:6UI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€0.45
GF Value